I Agree

We have updated our Privacy and Cookie Policy. By clicking "I Agree" below, you acknowledge that you accept our Privacy and Cookie Policy and Terms of Use.

PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
You are here: TIZIANA LIFE SC ORD 3P TILS Announcements

TIZIANA LIFE SC ORD 3P (TILS) Announcements

Date Time Source Announcement
16 Mar 2020 5:21 pm
RNS
Closing of Offer
12 Mar 2020 7:00 am
RNS
Tiziana U.S. Follow-On Offering of $10 million
11 Mar 2020 7:00 am
RNS
TZLS-501 / COVID-19
20 Feb 2020 10:30 am
RNS
Result of GM
17 Feb 2020 7:00 am
RNS
Proposed U.S. Public Offering of ADSs
04 Feb 2020 12:00 pm
RNS
Director/PDMR Shareholding
03 Feb 2020 7:00 am
RNS
Notice of GM
23 Jan 2020 7:00 am
RNS
Filing of SEC Form F-3
21 Jan 2020 2:45 pm
RNS
Director Appointment
14 Jan 2020 11:00 am
RNS
Director/PDMR Shareholding
13 Jan 2020 7:00 am
RNS
Proposed Cancellation from AIM
09 Jan 2020 7:00 am
RNS
Further re: Foralumab Phase 1 Trial
02 Jan 2020 3:00 pm
RNS
Director/PDMR Shareholding
04 Dec 2019 7:00 am
RNS
Foralumab Phase 1 Trial
20 Nov 2019 7:00 am
RNS
Issue of Equity and Directorate Change
01 Nov 2019 7:00 am
RNS
Issue of CLN
30 Oct 2019 10:31 am
RNS
Change to ADS ratio
30 Sep 2019 7:00 am
RNS
Half-year Report
16 Sep 2019 7:00 am
RNS
Further re: Update on IND Application
10 Sep 2019 7:00 am
RNS
Phase 1 Clinical Data
04 Sep 2019 7:00 am
RNS
Phase 2a Clinical Data
21 Aug 2019 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
06 Aug 2019 7:00 am
RNS
Proposed U.S. Public Offering
22 Jul 2019 7:00 am
RNS
Phase 2a Clinical Data
01 Jul 2019 7:00 am
RNS
Teplizumab Article
28 Jun 2019 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  10:54 am
RNS
Change of Adviser
25 Jun 2019 7:00 am
RNS
Director/PDMR Shareholding
24 Jun 2019 7:00 am
RNS
Article on Clinical Activity of OKT3
11 Jun 2019 7:00 am
RNS
Director/PDMR Shareholding
07 Jun 2019 9:44 am
RNS
Director/PDMR Shareholding
03 Jun 2019 7:00 am
RNS
PDMR Dealings
31 May 2019 11:05 am
RNS
Result of AGM
28 May 2019 7:00 am
RNS
9th Annual LD Micro Invitational
07 May 2019 7:00 am
RNS
Notice of AGM
02 May 2019 7:00 am
RNS
Director/PDMR Shareholding
01 May 2019 7:00 am
RNS
Update on IND Application
25 Apr 2019 5:00 pm
RNS
Director/PDMR Shareholding
  11:06 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
24 Apr 2019 12:55 pm
RNS
Reissue: Interim Clinical Data
  7:00 am
RNS
Interim Clinical Data
15 Apr 2019 5:45 pm
RNS
Holding(s) in Company
  5:45 pm
RNS
Holding(s) in Company
  5:45 pm
RNS
Holding(s) in Company
  5:45 pm
RNS
Holding(s) in Company
  5:45 pm
RNS
Holding(s) in Company
  5:45 pm
RNS
Holding(s) in Company
04 Apr 2019 7:00 am
RNS
Final Results
20 Mar 2019 7:00 am
RNS
IND Application Submitted for NASH Oral Treatment
07 Feb 2019 7:00 am
RNS
Directorate Change
11 Dec 2018 7:00 am
RNS
Exercise of Warrants & Issue of Equity
03 Dec 2018 7:00 am
RNS
Milciclib HCC Phase IIa Trial Enrollment Completed
28 Nov 2018 7:00 am
RNS
Foralumab: Phase 1 Trial with Nasal Administration
27 Nov 2018 7:00 am
RNS
Holding(s) in Company
26 Nov 2018 7:00 am
RNS
Statement re: ADSs
23 Nov 2018 5:00 pm
RNS
Closing of Offering and Total Voting Rights
20 Nov 2018 7:30 am
RNS
Discounted exercise prices of outstanding warrants
  7:00 am
RNS
Offer Pricing, Nasdaq Listing & Loan Conversion
26 Oct 2018 5:30 pm
RNS
Issue of Equity
18 Oct 2018 7:15 am
RNS
Amended Registration Statement filed with the SEC
16 Oct 2018 7:00 am
RNS
Milciclib synergistic activity presented at AASLD
25 Sep 2018 7:00 am
RNS
Tiziana announces Offering & Application to Nasdaq
24 Sep 2018 7:03 am
RNS
Interim Results for Six Months Ended 30 June 2018
  7:00 am
RNS
U.S. FDA Approval IND Nasal Foralumab Phase 1
13 Sep 2018 1:05 pm
RNS
PDMR Dealing
12 Sep 2018 7:00 am
RNS
PDMR dealings
11 Sep 2018 7:00 am
RNS
PDMR Dealing
24 Aug 2018 7:00 am
RNS
PDMR Dealing
21 Aug 2018 7:00 am
RNS
PDMR dealings
20 Aug 2018 7:00 am
RNS
PDMR Dealing
17 Aug 2018 7:00 am
RNS
PDMR Dealing
16 Aug 2018 9:00 am
RNS
Filing of Investigational New Drug application
27 Jul 2018 7:00 am
RNS
US Registration Statement for Proposed Offering
25 Jun 2018 10:49 am
RNS
Result of AGM
07 Jun 2018 7:01 am
RNS
Appointment of Broker
  7:00 am
RNS
Final Results
01 Jun 2018 7:00 am
RNS
Notice of AGM
23 May 2018 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
16 May 2018 7:00 am
RNS
Milciclib Phase 2a Trial - Tolerability Update
01 May 2018 3:00 pm
RNS
Grant of Options - Director Dealing
27 Apr 2018 7:00 am
RNS
Issue of Equity
19 Apr 2018 7:00 am
RNS
Subscription
16 Apr 2018 7:25 am
RNS
License Agreement
09 Apr 2018 8:25 am
RNS
Presentation at ASCO 3 June 2018
05 Apr 2018 7:00 am
RNS
Appointment of Broker
04 Apr 2018 7:00 am
RNS
Appointment of Director
05 Mar 2018 7:00 am
RNS
Placing to raise �600,000 and issue of equity
02 Mar 2018 12:09 pm
RNS
Statement re broker
22 Jan 2018 7:00 am
RNS
Placing
16 Jan 2018 7:00 am
RNS
Placing
15 Dec 2017 7:00 am
RNS
Placing and Issue of Equity
08 Dec 2017 7:00 am
RNS
Milciclib Phase 2a Trial Update
27 Nov 2017 7:00 am
RNS
Placing
23 Nov 2017 7:00 am
RNS
Phase II Clinical Trial Update
20 Nov 2017 7:00 am
RNS
Subscription
29 Sep 2017 7:00 am
RNS
Interim Results for Six Months Ended 30 June 2017
06 Sep 2017 7:00 am
RNS
A Proprietary Oral Formulation of Foralumab
31 Aug 2017 11:07 am
RNS
Grant of options - Director's dealing
16 Aug 2017 7:00 am
RNS
Conversion of outstanding loan notes
28 Jul 2017 7:00 am
RNS
Publication of Research Article on Foralumab
19 Jul 2017 7:00 am
RNS
Initiation of a Phase IIa Clinical Trial
12 Jul 2017 7:00 am
RNS
Proposed changes to CLNs and Warrant Terms
29 Jun 2017 11:21 am
RNS
Result of AGM
12 Jun 2017 7:00 am
RNS
Appointment of Dr Kunwar Shailubhai as CEO
08 Jun 2017 10:02 am
RNS
NOTIFICATION OF MAJOR INTEREST IN SHARES
  8:14 am
RNS
Bcl-3 pre-clinical update and Director's dealing
01 Jun 2017 7:00 am
RNS
2016 Annual Report and Accounts and notice of AGM
23 May 2017 7:00 am
RNS
Financial Results for Year Ended 31 December 2016
24 Apr 2017 7:14 am
RNS
Announces Approval of a Phase II Clinical Trial
21 Apr 2017 7:00 am
RNS
Announces Publication of Milciclib Clinical Trial
24 Mar 2017 7:00 am
RNS
Exercise of Warrants & Issue of Equity
14 Mar 2017 7:00 am
RNS
Arun Sanyal appointed to Scientific Advisory Board
16 Jan 2017 7:00 am
RNS
Warrant Expiry - Reminder
03 Jan 2017 7:00 am
RNS
Tiziana Life Sciences in-licenses NI-1201
16 Nov 2016 7:00 am
RNS
New Data with Foralumab
07 Nov 2016 12:29 pm
RNS
Grant of options
29 Sep 2016 7:00 am
RNS
Half-year Report
15 Sep 2016 7:00 am
RNS
Confirmation of Capital Reduction
18 Aug 2016 7:00 am
RNS
Change of Registered Office
18 Jul 2016 7:00 am
RNS
Tiziana acquires a unique bio-repository
30 Jun 2016 12:47 pm
RNS
Result of AGM
29 Jun 2016 7:00 am
RNS
Issue of Equity
10 Jun 2016 10:18 am
RNS
Grant of options and realisation bonus
07 Jun 2016 7:00 am
RNS
Final Results
01 Jun 2016 7:00 am
RNS
Partnership with Cardiff Researchers Wins Award
19 May 2016 7:00 am
RNS
Journal review of anti - CD3 monoclonal antibodies
04 May 2016 7:00 am
RNS
Appointment of Dr. Robert Evans
28 Apr 2016 7:00 am
RNS
Exercise of Warrants & Issue of Equity
04 Apr 2016 7:00 am
RNS
Chief Financial Officer Appointed
15 Mar 2016 7:00 am
RNS
Co-Founder and NED Prof Chris McGuigan Passes Away
16 Feb 2016 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
13 Jan 2016 7:00 am
RNS
Fund raising
11 Jan 2016 7:00 am
RNS
Development plans for foralumab & SAB appointments
08 Jan 2016 7:00 am
RNS
Update on Tiziana's Bcl-3 inhibitor
09 Dec 2015 8:00 am
RNS
Appoints James F. Tripp as Chief Operating Officer
08 Dec 2015 7:00 am
RNS
Fund raising
24 Nov 2015 7:00 am
RNS
Appointment of Non-Executive Director
30 Oct 2015 7:00 am
RNS
Exercise of Warrants & Issue of Equity
30 Sep 2015 7:00 am
RNS
Half Yearly Report
30 Jun 2015 12:48 pm
RNS
Result of AGM
05 Jun 2015 7:00 am
RNS
Final Results and Notice of AGM
07 May 2015 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
  7:10 am
RNS
Directorate Change
  7:05 am
RNS
Election to U.S. National Academy of Sciences
  7:00 am
RNS
Licences new anti-cancer stem cell technology
21 Apr 2015 7:00 am
RNS
Issue of convertible loan notes and warrants
31 Mar 2015 7:00 am
RNS
Placing to raise �2.55 million
20 Mar 2015 7:00 am
RNS
Exercise of Options and Issue of Equity
03 Mar 2015 7:00 am
RNS
Grant of Options
26 Jan 2015 7:00 am
RNS
Grant of Options
23 Jan 2015 2:04 pm
RNS
Board changes
20 Jan 2015 7:00 am
RNS
Licenses milciclib from Nerviano Medical Sciences
22 Dec 2014 7:00 am
RNS
Re Agreement with Novimmune
30 Sep 2014 7:00 am
GNW
Interim Results for the Six Months Ended 30 Jun...
12 Sep 2014 7:00 am
GNW
Scientific Advisory Board Appointment
05 Sep 2014 4:22 pm
GNW
Realisation bonuses
31 Jul 2014 2:41 pm
GNW
EXERCISE OF OPTIONS AND ISSUE OF EQUITY
03 Jul 2014 12:02 pm
GNW
Grant of Options
30 Jun 2014 7:02 am
GNW
Licensing agreement to develop stem cell based ...
25 Jun 2014 12:27 pm
GNW
Tiziana Life Sciences PLC : Result of AGM
20 Jun 2014 3:57 pm
GNW
Exercise of Options & Issue of Equity
17 Jun 2014 7:00 am
GNW
Issue of Convertible Loan Notes and Warrants
23 May 2014 1:35 pm
GNW
Notice of AGM
19 May 2014 7:01 am
GNW
Scientific Advisory Board Appointment
24 Apr 2014 11:15 am
GNW
First Day of Dealings

Top announcements

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close